Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1
Brief Summary: The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection


Options:
A: Arm Label: SOF/VEL; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo + Peg-IFN/Ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin, Drug: Comparator: placebo | Intervention Type: DRUG; Name: Comparator: Vaniprevir; Assigned to Arm(s): Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Pegylated-Interferon (Peg-IFN); Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Ribavirin; Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin
C: Arm Label: TMC12/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC12/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: PR48 Control; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: PegIFNα-2a; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6

Answer: D